AZTR Azitra, Inc.
Pharmaceutical Preparations · NYSE · SEC CIK 1701478 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-98.9%
TTM net income YoY20.5%
TTM EPS YoY71.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-146,468.5%
Net margin-119,566.6%
FCF margin-135,885.3%
EBITDA margin-144,793.5%
Returns
ROE-208.3%
ROA-143.8%
ROIC (approx.)-767.7%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets22.6%
Debt / equity0.00x
Current ratio3.80x
Interest coverage-903.38x
Cash quality & payout
Operating cash flow / net income1.14x
Accruals ratio19.5%
Payout ratio—
Capex / revenue114.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $0 | $7,500 |
| R&D expense | $4.84M | $4.72M |
| SG&A expense | $6.13M | $6.27M |
| Operating income | -$10.97M | -$10.99M |
| Interest expense | $7,587 | $12,160 |
| Pretax income | -$10.95M | -$8.96M |
| Income tax | $8,319 | $9,031 |
| Net income | -$10.96M | -$8.97M |
| EBITDA | -$10.83M | -$10.85M |
| EPS (basic) | -2.25 | -15.70 |
| EPS (diluted) | -2.25 | -15.70 |
| Weighted avg. shares (diluted) | 4.87M | 571,162 |
| Balance sheet | ||
| Cash & equivalents | $2.07M | $4.55M |
| Receivables | $912 | $233 |
| Current assets | $3.02M | $5.23M |
| PP&E, net | $548,591 | $653,957 |
| Intangibles | $316,673 | $246,420 |
| Total assets | $5.03M | $7.36M |
| Current liabilities | $1.07M | $1.38M |
| Total liabilities | $1.22M | $1.66M |
| Shareholders' equity | $3.80M | $5.70M |
| Shares outstanding | 1.07M | 1.15M |
| Cash flow statement | ||
| Operating cash flow | -$11.22M | -$10.18M |
| Capital expenditure | $24,213 | $8,569 |
| Free cash flow | -$11.25M | -$10.19M |
| Investing cash flow | -$182,909 | -$379,246 |
| Financing cash flow | $8.92M | $13.32M |
| Depreciation & amortization | $138,069 | $131,188 |
| Stock-based compensation | $62,744 | $245,053 |
Free plan shows the latest 2 periods; Pro shows all 4 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.